StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.47−0.39 (-4.96%)

Close on Nov 16, 2026Market cap $1.51BP/E –Yield –

SELLAS Life Sciences cash

Cash and short-term investments held at the end of each period.

SELLAS Life Sciences's cash was $134.71M at Sep 30, 2026. For fiscal 2025 it was $71.79M, up 413.3% from the year before. Over ten years it grew 48.3% a year on average. The highest annual figure on record is $71.79M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$71.79M+413.3%
FY2024Dec 31, 2024$13.99M+431.8%
FY2023Dec 31, 2023$2.63M-84.7%
FY2022Dec 31, 2022$17.23M-19.7%
FY2021Dec 31, 2021$21.46M-39.4%
FY2020Dec 31, 2020$35.40M+379.9%
FY2019Dec 31, 2019$7.38M+35.3%
FY2018Dec 31, 2018$5.45M-57.2%
FY2017Dec 31, 2017$12.75M+110.8%
FY2016Dec 31, 2016$6.05M+332.9%
FY2015Dec 31, 2015$1.40M-94.1%
FY2014Dec 31, 2014$23.65M-50.5%
FY2013Dec 31, 2013$47.79M+45.7%
FY2012Dec 31, 2012$32.81M-31.3%
FY2011Dec 31, 2011$47.79M+593.5%
FY2010Dec 31, 2010$6.89M+21.2%
FY2009Dec 31, 2009$5.68M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$134.71M+203.3%
Q2 FY2026Jun 30, 2026$138.34M+444.7%
Q1 FY2026Mar 31, 2026$107.10M+275.8%
Q4 FY2025Dec 31, 2025$71.79M+413.3%
Q3 FY2025Sep 30, 2025$44.42M+110.2%
Q2 FY2025Jun 30, 2025$25.40M+174.7%
Q1 FY2025Mar 31, 2025$28.50M+53.9%
Q4 FY2024Dec 31, 2024$13.99M+431.8%
Q3 FY2024Sep 30, 2024$21.13M+419.3%
Q2 FY2024Jun 30, 2024$9.25M-33.5%
Q1 FY2024Mar 31, 2024$18.52M-22.9%
Q4 FY2023Dec 31, 2023$2.63M-84.7%
Q3 FY2023Sep 30, 2023$4.07M-81.0%
Q2 FY2023Jun 30, 2023$13.91M-48.7%
Q1 FY2023Mar 31, 2023$24.00M+67.2%
Q4 FY2022Dec 31, 2022$17.23M-19.7%
Q3 FY2022Sep 30, 2022$21.45M-18.7%
Q2 FY2022Jun 30, 2022$27.09M-9.8%
Q1 FY2022Mar 31, 2022$14.35M-49.0%
Q4 FY2021Dec 31, 2021$21.46M-39.4%
Q3 FY2021Sep 30, 2021$26.38M+217.7%
Q2 FY2021Jun 30, 2021$30.02M+772.6%
Q1 FY2021Mar 31, 2021$28.13M+310.9%
Q4 FY2020Dec 31, 2020$35.40M+379.9%
Q3 FY2020Sep 30, 2020$8.30M-10.1%
Q2 FY2020Jun 30, 2020$3.44M-73.3%
Q1 FY2020Mar 31, 2020$6.85M+154.5%
Q4 FY2019Dec 31, 2019$7.38M+35.3%
Q3 FY2019Sep 30, 2019$9.23M-8.4%
Q2 FY2019Jun 30, 2019$12.87M+28.7%
Q1 FY2019Mar 31, 2019$2.69M-77.7%
Q4 FY2018Dec 31, 2018$5.45M-57.2%
Q3 FY2018Sep 30, 2018$10.08M+325.6%
Q2 FY2018Jun 30, 2018$10.00M+109.8%
Q1 FY2018Mar 31, 2018$12.09M+459.8%
Q4 FY2017Dec 31, 2017$12.75M+110.8%
Q3 FY2017Sep 30, 2017$2.37M–
Q2 FY2017Jun 30, 2017$4.77M–
Q1 FY2017Mar 31, 2017$2.16M–
Q4 FY2016Dec 31, 2016$6.05M–

More SELLAS Life Sciences figures

See a number that looks wrong?